Knoglemarvstransplantation og chimeric antigen receptor-T-celleterapi

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Knoglemarvstransplantation og chimeric antigen receptor-T-celleterapi. / Sengeløv, Henrik; Petersen, Søren Lykke.

I: Ugeskrift for Laeger, Bind 183, Nr. 42, V03210280, 18.10.2021.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Sengeløv, H & Petersen, SL 2021, 'Knoglemarvstransplantation og chimeric antigen receptor-T-celleterapi', Ugeskrift for Laeger, bind 183, nr. 42, V03210280. <https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2021-10/v03210280_web.pdf>

APA

Sengeløv, H., & Petersen, S. L. (2021). Knoglemarvstransplantation og chimeric antigen receptor-T-celleterapi. Ugeskrift for Laeger, 183(42), [V03210280]. https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2021-10/v03210280_web.pdf

Vancouver

Sengeløv H, Petersen SL. Knoglemarvstransplantation og chimeric antigen receptor-T-celleterapi. Ugeskrift for Laeger. 2021 okt. 18;183(42). V03210280.

Author

Sengeløv, Henrik ; Petersen, Søren Lykke. / Knoglemarvstransplantation og chimeric antigen receptor-T-celleterapi. I: Ugeskrift for Laeger. 2021 ; Bind 183, Nr. 42.

Bibtex

@article{b8a70169a4b34c0a83b72c95ba83e7d2,
title = "Knoglemarvstransplantation og chimeric antigen receptor-T-celleterapi",
abstract = "Malignant hematologic diseases resistant to chemotherapy can be cured by immune cellular therapy. Bone marrow transplantation (BMT) elicits a {"}pan-immunologic{"} attack, whereas therapy with chimeric antigen receptor (CAR)-T is a targeted attack. The immunologic activity after BMT can be adjusted by selection of donor cells before transplantation, or with post-BMT sequential chemotherapy. Many haematologic diseases are clonal, and the development of CAR-T cellular therapy directed against a variety of epitopes is under development as summarised in this review.",
keywords = "Bone Marrow Transplantation, Humans, Tissue Donors",
author = "Henrik Sengel{\o}v and Petersen, {S{\o}ren Lykke}",
year = "2021",
month = oct,
day = "18",
language = "Dansk",
volume = "183",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "42",

}

RIS

TY - JOUR

T1 - Knoglemarvstransplantation og chimeric antigen receptor-T-celleterapi

AU - Sengeløv, Henrik

AU - Petersen, Søren Lykke

PY - 2021/10/18

Y1 - 2021/10/18

N2 - Malignant hematologic diseases resistant to chemotherapy can be cured by immune cellular therapy. Bone marrow transplantation (BMT) elicits a "pan-immunologic" attack, whereas therapy with chimeric antigen receptor (CAR)-T is a targeted attack. The immunologic activity after BMT can be adjusted by selection of donor cells before transplantation, or with post-BMT sequential chemotherapy. Many haematologic diseases are clonal, and the development of CAR-T cellular therapy directed against a variety of epitopes is under development as summarised in this review.

AB - Malignant hematologic diseases resistant to chemotherapy can be cured by immune cellular therapy. Bone marrow transplantation (BMT) elicits a "pan-immunologic" attack, whereas therapy with chimeric antigen receptor (CAR)-T is a targeted attack. The immunologic activity after BMT can be adjusted by selection of donor cells before transplantation, or with post-BMT sequential chemotherapy. Many haematologic diseases are clonal, and the development of CAR-T cellular therapy directed against a variety of epitopes is under development as summarised in this review.

KW - Bone Marrow Transplantation

KW - Humans

KW - Tissue Donors

M3 - Tidsskriftartikel

C2 - 34709159

VL - 183

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 42

M1 - V03210280

ER -

ID: 305690506